CHANGE IN RATINGS
downgraded at Baird from Outperform to Neutral. $24 price target. Company posted poor third quarter results and lowered guidance.
downgraded at Oppenheimer from Buy to Neutral. Stock already pricing in potential favorable dialysis language in a year-end Medicare bill.
downgraded at Friedman, Billings Ramseyfrom Market Perform to Underperform. $35 price target. Credit trends are eroding much faster in the weakening housing market.
downgraded at JP Morgan from Overweight to Neutral. Valuation call. Stock has had a large run up, gaining 104% over the past year.
upgraded at Friedman, Billings Ramsey from Market Perform to Outperform. $14.50 price target. Expect more spending on HD video over the coming quarters.
upgraded at Friedman, Billings Ramsey to Outperform. Company posted a strong quarter, and the fundamental outlook remains strong into 2008. $41 price target.
upgraded at CIBC from Sector Perform to Outperform. $50 price target. Company stands out in a bleak adult apparel business.
downgraded at Morgan Stanley to Underweight. Stock not expected to gain as much as its peers over the next 12 to 18 months. Ambac or Primus offer better upside potential at current levels.
upgraded at Bear Stearns from Underperform to Peer Perform. Valuation call, as the stock is down 27% over the past three months. Estimates cut to reflect increased competition, but this is already reflected in the stock.
upgraded at CIBC from Underperform to Sector Perform. Company is realizing higher margins in the International Industrial segment.
upgraded at Bernstein from Underperform to Market Perform. $80 price target. Stock is down 18% over the past 6 months, and is beginning to look attractive as a potential takeover target.
upgraded at JP Morgan from Neutral to Overweight. Fourth quarter should mark a business trough, and the stock is down 25% from its July highs.
downgraded at CIBC from Outperform to Sector Perform. Current weakness in the Missy space suggest that second half expectations are too high.
upgraded at Merrill from Neutral to Buy. $76 price target. Valuation does not reflect highly predictable earnings and cash flow.
downgraded at Merrill from Buy to Neutral. Valuation call, though 2008 estimates are being raised to reflect higher cornbelt nitrogen prices.
downgraded at JP Morgan from Overweight to Neutral. Earnings growth is slowing, and integration and service issues persist.
downgraded at Cowen from Outperform to Neutral. Lack of conviction that telaprevir will retain its best in class profile.
downgraded at CIBC from Outperform to Sector Perform. $51 price target. Company posted a good quarter, but poor sales visibility leads to an uncertain margin outlook.
STOCK COMMENTS / EPS CHANGES
target raised at RBC. Shares of AAPL now seen reaching $205. Mac momentum is ramping, and the company is reaching an inflection point in PC market share. Outperform rating.
2007 numbers boosted at Morgan Stanley to $2.77 a share. Company delivered a solid quarter, and margins remain robust. Overweight rating and new $64 price target.
estimates, target cut at Morgan Stanley through 2009. Loads are flat, and the company is having trouble keeping a lid on costs. Equal-weight rating and new $42 price target.
2008 estimates cut at Morgan Stanley to $4.95 a share. M&A and leveraged loans will cut into earnings. Still, the stock should outperform its peers. Overweight rating and $59 price target.
estimates, target upped at Morgan Stanley. PMCS now seen reaching $12 a share. Estimates also raised, as the component vendors continue to see positive order trends. Overweight rating.
estimates raised at Morgan Stanley through 2009. Large projects driving earnings. Spanish tariff structure may also become more favorable. Overweight rating.
target lowered at Morgan Stanley to $24 a share. AOL and cable expected to post lower earnings. Overweight rating.
2009 numbers increased at Morgan Stanley. September quarter sales were weak, but the company is keeping a lid on costs. Equal-weight rating and new $30 price target.